Germany
Every company in the roster headquartered in Germany.
Every company in the roster headquartered in Germany.
13 of 13 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
BioNTechBNTX · Nasdaq | 9 assets: 4 Ph 3, 3 Ph 2, 2 Ph 1 | Trastuzumab pamirtecanPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Nov 2026Beruzatatug pelitecan · Phase 2 | $21.1B | $9.0BDec 2025 | Cash-flow positive | $2.4B |
BayerBAYN · Xetra | 21 assets: 12 approved, 3 Ph 3, 3 Ph 2, 1 Ph 1, 2 other | MiglitolUS approval withdrawn · Type 2 DiabetesPartial signal | Dec 2026Mosliciguat · Phase 2 | — | $6.6BMar 2026 | Ended Aug 2026 | ~$6.6B |
Fresenius Medical Care AGFME · Xetra | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Boehringer IngelheimPrivate | 39 assets: 17 approved, 9 Ph 3, 8 Ph 2, 4 Ph 1, 1 other | PramipexoleUS approval withdrawn · Parkinson's DiseasePartial signal | 8 Dec 2026survodutide · Phase 1 | — | — | — | — |
CatalYm GmbHPrivate | 1 asset: 1 Ph 2 | VisugromabPhase 2 · Non-Small Cell Lung CancerWeak signal | 30 Apr 2028Visugromab · Phase 1/2 | — | — | — | — |
| 11 assets: 11 approved | Approved assets only | None on record | — | — | — | — | |
Exciva GmbHPrivate | 2 assets: 2 Ph 3 | DeramciclanePhase 2/3 · Alzheimer's Disease | Jan 2029Deramciclane · Phase 2/3 | — | — | — | — |
MedicePrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Midas Pharma GmbHPrivate | 1 asset: 1 other | Ranibizumab (Ranivisio)Age-Related Macular Degeneration | None on record | — | — | — | — |
NovaliqPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Priavoid GmbHPrivate | 1 asset: 1 Ph 2 | PRI-002Phase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
selectION TherapeuticsPrivate | 1 asset: 1 Ph 1 | si-544Phase 1 · PsoriasisPartial signal | None on record | — | — | — | — |
Tubulis GmbHPrivate | 1 asset: 1 Ph 2 | TUB-030Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.